Optimizing the tumor shrinkage threshold for evaluating immunotherapy efficacy for advanced non-small-cell lung cancer

Purpose The rise of immune checkpoint inhibitors (ICIs) in recent years has coincided with unusual clinical response patterns. Modification of the sum of longest diameters (SLD)-based threshold that reflecting dynamic change of the tumor burden and predicting response to ICIs, may markedly improve c...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cancer research and clinical oncology 2023-03, Vol.149 (3), p.1103-1113
Main Authors: Du, Wei, Chen, Chen, Luo, Lin-feng, He, Li-na, Wang, Yixing, Zhang, Xuanye, Zhou, Yixin, Lin, Zuan, Hong, Shaodong
Format: Article
Language:English
Subjects:
Cancer Research
Carcinoma, Non-Small-Cell Lung - pathology
Hematology
Humans
Immune checkpoint inhibitors
Immunotherapy
Internal Medicine
Lung cancer
Lung Neoplasms - pathology
Medical prognosis
Medicine
Medicine & Public Health
Metastases
Metastasis
Non-small cell lung carcinoma
Oncology
Original Article – Clinical Oncology
Treatment Outcome
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose The rise of immune checkpoint inhibitors (ICIs) in recent years has coincided with unusual clinical response patterns. Modification of the sum of longest diameters (SLD)-based threshold that reflecting dynamic change of the tumor burden and predicting response to ICIs, may markedly improve current treatment regimens. Methods The baseline and post-treatment SLD of target lesion was recorded and the maximum percent change of the SLD from baseline was designated as SLD-change score. The optimal cut-off value was obtained using the X-tile program. The relationship between SLD-change score and survival outcome (PFS, OS) was evaluated. Results 10% cut-off value of SLD-change score was found to be most distinctive for PFS. Responders defined according to this cut-off value showed a significant improvement for PFS and OS. Bone metastasis and brain metastasis were also two independent prognostic factors of PFS and OS, respectively. Conclusions 10% SLD change score could discriminate for ICIs treatment response, which holds great promise in promoting the development of precise immunotherapeutic strategy.
ISSN:0171-5216
1432-1335
DOI:10.1007/s00432-022-03978-3